We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
DIASOURCE (A Biovendor Company)

Download Mobile App





Sensor for Faster, More Accurate COVID-19 Tests Could Revolutionize Virus Testing

By LabMedica International staff writers
Posted on 30 Mar 2022

PCR tests are highly accurate, but require complicated sample preparation, with results taking hours or even days to process in a laboratory. More...

On the other hand, rapid tests, which look for the existence of antigens, are less successful at detecting early infections and asymptomatic cases and can lead to erroneous results. Now, a new technology addresses the limitations of these two most widely used types of COVID-19 tests.

A COVID-19 sensor developed at Johns Hopkins University (Baltimore, MD, USA) could revolutionize virus testing by adding accuracy and speed to a process that frustrated many during the pandemic. The sensor, which requires no sample preparation and minimal operator expertise, offers a strong advantage over existing testing methods, especially for population-wide testing.

The sensor is nearly as sensitive as a PCR test and as convenient as a rapid antigen test. During initial testing, the sensor demonstrated 92% accuracy at detecting SARS-COV-2 in saliva samples - comparable to that of PCR tests. The sensor was also highly successful at rapidly determining the presence of other viruses, including H1N1 and Zika. The sensor is based on large area nanoimprint lithography, surface enhanced Raman spectroscopy (SERS), and machine learning. It can be used for mass testing in disposable chip formats or on rigid or flexible surfaces.

Key to the method is the large-area, flexible field enhancing metal insulator antenna (FEMIA) array developed by the researchers. The saliva sample is placed on the material and analyzed using surface-enhanced Raman spectroscopy, which employs laser light to examine how molecules of the examined specimen vibrate. Because the nanostructured FEMIA strengthens the virus's Raman signal significantly, the system can rapidly detect the presence of a virus, even if only small traces exist in the sample. Another major innovation of the system is the use of advanced machine learning algorithms to detect very subtle signatures in the spectroscopic data that allow researchers to pinpoint the presence and concentration of the virus. The sensor material can be placed on any type of surface, from doorknobs and building entrances to masks and textiles. The sensor could potentially be integrated with a hand-held testing device for fast screenings at crowded places like airports or stadiums, according to the researchers. The team continues working to further develop and test the technology with patient samples.

"Our platform goes beyond the current COVID-19 pandemic," added Barman. "We can use this for broad testing against different viruses, for instance, to differentiate between SARS-CoV-2 and H1N1, and even variants. This is a major issue that can't be readily addressed by current rapid tests," said Ishan Barman, an associate professor of mechanical engineering, and one of the senior authors of the study.

"Using state of the art nanoimprint fabrication and transfer printing we have realized highly precise, tunable, and scalable nanomanufacturing of both rigid and flexible COVID sensor substrates, which is important for future implementation not just on chip-based biosensors but also wearables," said David Gracias, a professor of chemical and biomolecular engineering, and one of the senior authors of the study.

Related Links:
Johns Hopkins University 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.